April 26, 2011Current Opinion in Oncology
Phase 1 clinical trials for sarcomas: the cutting edge
Authors
Discussion
Loading...
Member takes
Implication
Review demonstrates clinical efficacy of targeted agents in advanced sarcoma, highlighting the need for predictive biomarkers to guide therapy.
Key Points
- To review recent early-phase clinical trial data on targeted and novel therapeutics for advanced sarcoma and evaluate challenges in biomarker-driven treatment strategies.
- Literature review analyzing recent phase 1 clinical trials evaluating targeted small-molecule inhibitors, monoclonal antibodies, and combination chemotherapies.
- Assessed treatment outcomes across specific sarcoma histologies characterized by defined genetic translocations and kinase activation.
- Targeted phase 1 agents demonstrated single-agent activity, including insulin-like growth factor-1 receptor antibodies in Ewing sarcoma and crizotinib in ALK-rearranged inflammatory myofibroblastic tumors.
- Preliminary efficacy was reported with Apo2L/TRAIL agonists in chondrosarcoma, cediranib in alveolar soft part sarcoma, rexin-G in osteosarcoma, and trabectedin combinations in soft tissue sarcoma.
- Clinical benefit was most pronounced in sarcomas harboring recurrent translocations or activated kinase pathways, underscoring the necessity of predictive biomarkers for patient selection.
Cite This Study
Subbiah et al. (2011) studied this question.